QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.004242v1 33/11/1657    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sakai, N. Articles by Fujita, S. Search for Related Content PubMed PubMed Citation Articles by Sakai, N. Articles by Fujita, S.

IMPORTANCE OF CYP2D3 IN POLYMORPHISM OF DIAZEPAM P-HYDROXYLATION IN RATS

Laboratory of Toxicology, Department of Environmental Veterinary Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan (N.S., K.S., H.-S.K., A.K., M.I., S.F.); and Department of Chemical Biology, Osaka City University Medical School, Osaka, Japan (Y.F.)

Diazepam was metabolized to three primary metabolites, 3-hydroxy-diazepam, N-desmethyl-diazepam, and p-hydroxy-diazepam. Our previous studies reported metabolic position-specific inter- or intrastrain differences in diazepam metabolism among Sprague-Dawley, Brown Norway, Dark Agouti, and Wistar rats. Especially, there were marked (300 fold) inter- or intrastrain differences in diazepam p-hydroxylation activity at low concentration of substrate. In this study, we investigated the enzyme that catalyzes diazepam p-hydroxylation. The activity toward diazepam p-hydroxylation was inhibited by anti-cytochrome P450 2D (CYP2D) antibody, suggesting that this activity was catalyzed by CYP2D isoforms. Comparing the expression levels of the CYP2D subfamily in liver microsomes from various strains of rats using anti-CYP2D2 antibody, we found that there was a band of protein that was consistent with the phenotype of diazepam p-hydroxylation. N-terminal amino acid sequences of the specific protein exactly corresponded to those of CYP2D3, indicating that CYP2D3 might be involved in diazepam p-hydroxylation. Moreover, using rat CYP2D isoforms expressed in yeast, we tested CYP2Ds to catalyze diazepam p-hydroxylation. CYP2D1 and CYP2D2 practically did not participate in diazepam metabolism. On the other hand, diazepam p-hydroxylation was catalyzed by CYP2D3. CYP2D4 had high activity toward diazepam N-desmethylation, but not p-hydroxylation. In conclusion, the polymorphic expression of CYP2D3 caused the inter- or intrastrain differences in diazepam p-hydroxylation among rat strains or individuals.

This article has been cited by other articles:

				N. Sakai, K. Saito, K. Q. Sakamoto, M. Ishizuka, and S. Fujita Genetic Basis of Inter- and Intrastrain Differences in Diazepam p-Hydroxylation in Rats Drug Metab. Dispos., February 1, 2009; 37(2): 268 - 271. [Abstract] [Full Text] [PDF]

				T. Ito, M. Takahashi, K. Sudo, and Y. Sugiyama Marked Strain Differences in the Pharmacokinetics of an {alpha}4beta1 Integrin Antagonist, 4-[1-[3-Chloro-4-[N-(2-methylphenyl)-ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]-methoxybenzoic Acid (D01-4582), in Sprague-Dawley Rats Are Associated with Albumin Genetic Polymorphism J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 124 - 132. [Abstract] [Full Text] [PDF]